XTL Biopharmaceuticals
XTLB
2 hedge funds and large institutions have $2.45M invested in XTL Biopharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0.6% less ownership
Funds ownership: 5.34% → 4.73% (-0.6%)
26% less capital invested
Capital invested by funds: $3.32M → $2.45M (-$869K)
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$342K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$7K |
XTLB Hedge Fund Activity: Q2 2015 in Review
2 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2015, worth a combined $2.45M — down 26% from $3.32M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of XTLB and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Sabby Management, cutting an estimated $342K.
- 2 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2015, down from 3 in Q1 2015.
- Funds reported $2.45M of XTL Biopharmaceuticals stock for Q2 2015, down 26% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q2 2015 and 1 closed out, a net change of -1 holder.
- The largest XTL Biopharmaceuticals seller in Q2 2015 was Sabby Management, an estimated $342K sold.
Based on aggregated 13F filings for Q2 2015.